The Rx Recap: April 27-May 3

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

New Cancer Research and Treatment Center in Development in London

Research covered by BioPharm International reports that Aviva Capital Partners and developer Socius will invest £1 billion (US$1.33 billion) to build a major cancer research and treatment center at the London Cancer Hub in Sutton, London. Slated to create 3,000 jobs and generate £1.2 billion annually for the UK economy, the project will offer 1 million square feet of lab, manufacturing, and office space for life sciences firms alongside academic and clinical collaborators. Designed to be net-zero carbon, the site will support drug discovery, diagnostics, and cancer treatment innovation, further anchoring Sutton as a global leader in oncology research.

Q&A: As Closures Mount, Independent Pharmacies Must Diversify Services

Research reported in Drug Topics underscores the growing crisis facing U.S. independent pharmacies, with over 300 closures since December 2024, largely attributed to unsustainable reimbursement rates from pharmacy benefit managers and stalled reforms. At the American Associated Pharmacies 2025 conference, Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association, emphasized the urgent need for diversification, urging pharmacies to adopt services like long-term care at home, compounding, immunizations, and clinical outreach. Hoey warned that without fair reimbursement and proactive adaptation, pharmacy deserts will grow, jeopardizing patient access and outcomes.

Recapping Every FDA Approval Announced in April for Cancer Care

This past month, the FDA approved several oncology treatments across a range of cancers, which Cure outlined in a recent breakdown. Highlights include Opdivo plus Yervoy for colorectal and liver cancers, with full approvals based on CHECKMATE trials. Vitrakvi (larotrectinib) received full approval for NTRK-positive solid tumors, transitioning from its earlier accelerated status. Penpulimab-kcqx, a PD-1 inhibitor, was approved for nasopharyngeal carcinoma both as part of a chemo combination and as a monotherapy. Lastly, Tepylute, a ready-to-dilute version of thiotepa, was approved for breast and ovarian cancers—streamlining preparation in clinical settings. These approvals represent major strides in personalized and practical cancer care.

Elizabeth Gandee, APRN-CNP, highlights gaps in women's menopause knowledge

In a recent interview with Contemporary OB/GYN, Elizabeth Gandee, APRN-CNP, of The Ohio State University Wexner Medical Center, highlighted the findings of a national survey that shed light on women’s perceptions of perimenopause and menopause. The survey, which included over 1,000 women aged 18 to 60, revealed widespread misconceptions and a lack of education surrounding this critical life stage.

Among the key findings, 61% of respondents expected to experience menopause between ages 41 and 50—overlooking that perimenopausal symptoms can begin as early as the late 30s. Only half of respondents believed diet and exercise could ease symptoms, despite strong evidence supporting lifestyle interventions in symptom relief and bone health. Perhaps most strikingly, just 25% of women considered hormone therapy to be a safe and effective option, contradicting established medical guidance.

"It Costs Too Much," Americans Say About Skipping Necessary Medical Care: Survey Findings

Research reported in Patient Care highlights growing concerns about the impact of rising health care costs on patient behavior and employer-sponsored insurance. A Pollfish survey of 2,500 insured adults found that 38% delayed or skipped care due to cost—a 41% increase from 2023—with 42% of those reporting worsened conditions. High premiums and out-of-pocket costs were key barriers, while 67% of respondents said health benefits influence job decisions, and 28% would accept lower pay for better coverage. The findings suggest that financial strain is leading to deferred care, worsening outcomes, and increased stress for both patients and providers.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.